June 2021
Construction begins
Innoxel Lifesciences, headquartered in Vadodara, India, specializes in the aseptic and terminal sterilized production of injectable vials, pre-filled syringes, and oral liquids. As a comprehensive pharmaceutical company, we possess Research & Formulation Development and manufacturing capabilities, particularly in patented drug-delivery formulations within specialized therapies like oncology and critical care. Our primary focus is on regulated markets such as the USA, to enhance India's expanding global market footprint by ensuring unmatched quality standards.
Established in 2020, Innoxel Lifesciences stands out as a unique greenfield site. We have meticulously planned, constructed, and are currently operational, ensuring adherence to EU GMP, UK MHRA, and US FDA standards. The initial batch of ANDA filings with the US FDA via Innoxel is scheduled for Q1 2024, setting the stage for a potential US FDA inspection in early 2025.
Innovate. Collaborate. Elevate.
Start Your Journey with Innoxel!